ACP
JANX icon

Altitude Crest Partners’s Janux Therapeutics JANX Stock Holding History

Altitude Crest Partners’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-193,300
Closed -$7.28M – 17
2024
Q1 		$7.28M Buy
+193,300
New +$4.21M 3.12% 10

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Altitude Crest Partners's JANX Position: Q2 2024 in Review

Altitude Crest Partners sold out of Janux Therapeutics (JANX) in Q2 2024, closing a stake of 193,300 shares — an estimated $7.28M sold.

Altitude Crest Partners first reported a position in JANX in Q1 2024 and held it in 1 quarter. The position peaked at $7.28M in Q1 2024. 155 funds tracked by Wall St. Rank hold JANX as of Q2 2024.

  • Altitude Crest Partners reported no remaining Janux Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 193,300 Janux Therapeutics shares in Q2 2024, an estimated $7.28M.
  • Altitude Crest Partners first reported a position in Janux Therapeutics in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's Janux Therapeutics position peaked at $7.28M in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.